2023
DOI: 10.1093/ofid/ofad004
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review

Abstract: Human papillomavirus (HPV) is an important cause of anogenital and oropharyngeal cancers, anogenital warts, and recurrent respiratory papillomatosis. Beginning in 2019, US guidelines recommend shared clinical decision-making (SCDM) for HPV vaccination among mid-adults (27–45 years). We conducted a narrative review of existing literature on HPV vaccination in mid-adults. Available evidence demonstrates that HPV vaccination in mid-adults is safe, efficacious, and likely to benefit both HPV-naïve mid-adults and t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 67 publications
0
3
0
Order By: Relevance
“… 14 Although it is likely that most individuals in this age group have been exposed to some HPV subtypes, many may remain protected against some HPV subtypes covered by the nonavalent vaccine, thereby mitigating risk for developing some HPV-associated malignancies. 15 , 16 …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“… 14 Although it is likely that most individuals in this age group have been exposed to some HPV subtypes, many may remain protected against some HPV subtypes covered by the nonavalent vaccine, thereby mitigating risk for developing some HPV-associated malignancies. 15 , 16 …”
Section: Introductionmentioning
confidence: 99%
“… 23 , 24 However, it is unclear whether the pattern of uptake is similar among adults. Based on already existing disparities in HPV vaccine uptake in general, as well as the shared decision-making model of this expanded recommendation, 16 we hypothesized that there are significant disparities in HPV vaccine uptake among racial/ethnic minorities compared to Non-Hispanic White individuals aged 27–45 years, and that racial/ethnic minorities would be disproportionately impacted. We also hypothesized that due to the shared-decision-making model of the expanded age of eligibility, individuals without a regular provider would be less likely to receive the HPV vaccine.…”
Section: Introductionmentioning
confidence: 99%
“…This is founded on the results of two phase III trials that proved good vaccine efficacy in adult women that were HPV DNA-negative at the time of vaccination. However, there is still a limited understanding of the effectiveness of HPV vaccination in adult women and its impact on reducing cervical cancer incidence and mortality and the reduction of screening needs [ 20 , 21 ]. In addition, there are only scant data on acceptability of the HPV vaccine among adult women and men and on vaccination coverage among non-targeted adult women and men in Europe.…”
Section: Introductionmentioning
confidence: 99%